Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy ; volume:5 ; number:1 ; day:17 ; month:10 ; year:2017 ; pages:1-8 ; date:12.2017
Journal for ImmunoTherapy of Cancer ; 5, Heft 1 (17.10.2017), 1-8, 12.2017
- Creator
-
Jeyakumar, Ghayathri
- Contributor
-
Kim, Seongho
Bumma, Naresh
Landry, Craig
Silski, Cynthia
Suisham, Stacey
Dickow, Brenda
Heath, Elisabeth
Fontana, Joseph
Vaishampayan, Ulka
SpringerLink (Online service)
- DOI
-
10.1186/s40425-017-0287-5
- URN
-
urn:nbn:de:1111-20171213878
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jeyakumar, Ghayathri
- Kim, Seongho
- Bumma, Naresh
- Landry, Craig
- Silski, Cynthia
- Suisham, Stacey
- Dickow, Brenda
- Heath, Elisabeth
- Fontana, Joseph
- Vaishampayan, Ulka
- SpringerLink (Online service)
Other Objects (12)
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Antiangiogenic therapy
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Image-based modeling of vascular organization to evaluate anti-angiogenic therapy
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Antiangiogenic therapy
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Image-based modeling of vascular organization to evaluate anti-angiogenic therapy
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Antiangiogenic therapy
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Image-based modeling of vascular organization to evaluate anti-angiogenic therapy
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma